<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122657">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01843972</url>
  </required_header>
  <id_info>
    <org_study_id>1334.1</org_study_id>
    <secondary_id>2012-005721-67</secondary_id>
    <nct_id>NCT01843972</nct_id>
  </id_info>
  <brief_title>Safety of Single Rising Doses and Relative Bioavailability of BI 691751</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 691751 in Healthy Male Volunteers in a Randomised, Single-blind, Placebo-controlled Design (Part I) and Investigation of Relative Bioavailability of BI 691751 Given as Tablet and Oral Solution to Healthy Male Subjects in an Open, Randomised, Single-dose, Single Period Parallel Group Design (Part II).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of  single
      rising doses of BI 691751 in healthy male subjects  (part I).

      To investigate  the relative bioavailability of BI 691751 given as tablet versus oral
      solution (part II)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>AUC0-72h (area under the concentration-time curve of the analyte of BI 691751 in plasma over the time interval from 0 to 72 h) (part II)</measure>
    <time_frame>up to 72 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte of BI 691751 in plasma) (part II)</measure>
    <time_frame>up to 72 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum measured concentration of BI 691751 in plasma) (part I)</measure>
    <time_frame>up to 240 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 extrapolated to infinity) (part I)</measure>
    <time_frame>up to 240 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of BI 691751 in plasma over the time interval from 0 up to the last quantifiable data point)</measure>
    <time_frame>up to 240 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2 (terminal half-life of the analyte of BI 691751 in plasma) (part I)</measure>
    <time_frame>up to 240 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum measured concentration of BI 691751) (part I)</measure>
    <time_frame>up to 240 hours postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 691751 dose 2 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 3 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 4 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 5 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 6 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 dose 7 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751dose 1 (part I)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (part I)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 tablet (part II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose given as 1 tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 691751 solution (part II)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single dose given as oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 6</description>
    <arm_group_label>BI 691751 dose 6 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution</description>
    <arm_group_label>BI 691751 solution (part II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo solution</description>
    <arm_group_label>Placebo (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 2</description>
    <arm_group_label>BI 691751 dose 2 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 5</description>
    <arm_group_label>BI 691751 dose 5 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>1 tablet</description>
    <arm_group_label>BI 691751 tablet (part II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 3</description>
    <arm_group_label>BI 691751 dose 3 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 69175, dose 4</description>
    <arm_group_label>BI 691751 dose 4 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 691751, dose 7</description>
    <arm_group_label>BI 691751 dose 7 (part I)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>oral solution BI 69175, dose 1</description>
    <arm_group_label>BI 691751dose 1 (part I)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male subjects

          2. Subjects must be able to understand and comply with study requirements

          3. Age from 18 to 55 years

          4. BMI range: from 18.5 to 29.9 kg/m2

          5. Known genotype as specified in the study protocol

        Exclusion criteria:

        1. Any relevant deviation from healthy conditions
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1334.1.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
